Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-8242
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-8242 is an orally bioavailable, small-molecule inhibitor of the human double minute 2 (HDM2/MDM2) protein. It disrupts the interaction between HDM2 and the tumor suppressor protein p53, thereby stabilizing and activating p53. This leads to cell cycle arrest or apoptosis in cancer cells with wild-type TP53. MK-8242 was developed as a potential antineoplastic agent for various cancers, including advanced solid tumors and acute myeloid leukemia (AML). The drug was initially developed by Merck Sharp & Dohme (Merck & Co.), but its development has been discontinued[1][3][4][5][7].
- Other names
- hdm2 inhibitor mk-8242hdm-2 inhibitor mk-8242hdm 2 inhibitor mk-8242
02
Targets
MDM2 (Mouse double minute 2 homolog)
Beyond the preview
Go deeper on MK-8242.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-8242.